000			03641nam a22005297a 4500
008			180730s20182018 xxu||||| |||| 00| 0 eng d
022			_a1351-5101
024			_a10.1111/ene.13741 [doi]
040			_aOvid MEDLINE(R)
099			_a29953701
245			_aDifferential Leukocyte Counts on Admission Predict Outcomes in Acute Ischemic Stroke Patients treated with Intravenous Thrombolysis.
251			_aEuropean Journal of Neurology. 25(12):1417-1424, 2018 12.
252			_aEur J Neurol. 25(12):1417-1424, 2018 12.
253			_aEuropean journal of neurology
260			_c2018
260			_fFY2019
266			_d2018-07-30
269			_fFY2018
520			_aCONCLUSIONS: Admission differential leukocyte counts are independently associated with clinical outcomes in AIS patients treated with IVT and might represent potential inflammatory targets for adjunctive neuroprotection in this stroke subgroup. This article is protected by copyright. All rights reserved.
520			_aCopyright This article is protected by copyright. All rights reserved.
520			_aMETHODS: Consecutive AIS patients receiving IVT were evaluated at two stroke centers. Differential leukocyte counts and neutrophil-lymphocyte ratio (NLR) were determined during initial 12 hours of admission. Efficacy outcomes involved favorable functional outcome (FFO) [mRS-scores of 0-1] and functional independence (FI) [mRS-scores of 0-2] at three months; whereas safety outcomes were symptomatic intracranial hemorrhage (sICH) and three-month mortality.
520			_aOBJECTIVE: To determine the association of differential leukocyte counts on admission with efficacy and safety outcomes in acute ischemic stroke (AIS) patients treated with intravenous thrombolysis (IVT).
520			_aRESULTS: Among 657 IVT-treated AIS patients, mean age was 64+/-14, 50% were female and median NIHSS was 7 points [IQR 4-13]. Lower neutrophil, leukocyte and NLR counts were observed in patients with 3-month FFO and FI, whereas higher counts were observed in patients who expired at three months. The best discriminative factor for 3-month FFO and FI were NLR<2.2 (sensitivity 51.4%, specificity 63.1%) and leukocyte <8,100/muL (sensitivity 57.5%, specificity 55.1%), respectively. After adjustment for potential confounders, NLR <2.2 was associated with higher odds of FFO (OR: 1.56; 95%CI: 1.08-2.24; p=0.018), leukocyte count <8,100/muL was associated with higher odds of 3-month FI (OR: 1.69; 95%CI: 1.11-2.57; p=0.014) and lower odds of 3-month mortality (OR: 0.31; 95%CI: 0.16-0.60; p=0.001), whereas combined neutrophil (<6,800/muL) and leukocyte (<8,100/muL) counts were associated with 3-month FI (OR: 1.73; 95%CI: 1.13-2.67; p=0.012).
546			_aEnglish
650			_a*Brain Ischemia/bl [Blood]
650			_a*Fibrinolytic Agents/tu [Therapeutic Use]
650			_a*Leukocyte Count
650			_a*Stroke/bl [Blood]
650			_a*Thrombolytic Therapy/mt [Methods]
650			_aAdministration, Intravenous
650			_aAged
650			_aBrain Ischemia/dt [Drug Therapy]
650			_aFemale
650			_aHospitalization
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aPrognosis
650			_aStroke/dt [Drug Therapy]
650			_aTreatment Outcome
656			_aCritical Care Medicine
657			_aJournal Article
700			_aChang, Jason J
790			_aAlexandrov AV, Broce M, Chang JJ, Goyal N, Kerro A, Malhotra K, Pandhi A, Shahripour RB, Tsivgoulis G
856			_uhttps://dx.doi.org/10.1111/ene.13741 _zhttps://dx.doi.org/10.1111/ene.13741
942			_cART _dArticle
999			_c3606 _d3606